市場調査レポート
商品コード
1496762
臨床試験用品市場:フェーズ、タイプ、製品、治療分野、エンドユーザー別-2024-2030年の世界予測Clinical Trial Supplies Market by Phase (Phase I, Phase II, Phase III), Type (Biologic Drugs, Medical Devices, Small-Molecules), Product, Therapeutic Area, End User - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
臨床試験用品市場:フェーズ、タイプ、製品、治療分野、エンドユーザー別-2024-2030年の世界予測 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 199 Pages
納期: 即日から翌営業日
|
臨床試験用品市場規模は、2023年に33億5,000万米ドルと推計され、2024年には36億4,000万米ドルに達し、CAGR 8.43%で2030年には59億2,000万米ドルに達すると予測されています。
調査は、臨床研究の基本的かつ複雑な要素であり、最終的には治療法のブレークスルーを成功させ、患者の治療経路を画期的に改善する道を開くのに役立っています。これらの供給品は、前臨床試験から市販後調査までの様々な研究フェーズに対応し、臨床試験のシームレスな管理と実施を促進します。感染症や慢性疾患の世界の流行と、それに伴う製薬・バイオ医薬品業界の研究開発費を伴う臨床試験の増加は、市場の成長を刺激します。臨床試験用品に関連する高コスト、供給に関する厳しい規制、国境を越えたロジスティクスの課題は、市場の成長を制限します。医薬品開発への重点化と患者中心の臨床試験へのシフトは、臨床試験患者の募集、試験登録、参加者維持の改善につながる可能性があります。加えて、多様なテーマ_KEYWORDにおける継続的な進歩は、製薬・バイオ医薬品企業にとって新たな研究の道を開くものと期待されます。
主な市場の統計 | |
---|---|
基準年[2023] | 33億5,000万米ドル |
予測年[2024] | 36億4,000万米ドル |
予測年 [2030] | 59億2,000万米ドル |
CAGR(%) | 8.43% |
地域別インサイト
米国とカナダを中心とする南北アメリカでは、慢性疾患の診断率が高く、ヘルスケアインフラがしっかりしているため、臨床試験用品への依存度が高いです。過去1年間に登録された主な特許は、サプライチェーンモデルの最適化と、試験供給と需要を一致させるための高度なアナリティクスの採用に関連するものでした。欧州連合(EU)、中東・アフリカでは、ヘルスケアへのアクセスや支出に格差があるため、多様なニーズが見られます。欧州では、研究開発への重点的な投資と高齢者人口の急増に後押しされ、テーマ_KEYWORDに対する需要が安定しています。対照的に、中東やアフリカ諸国は新興市場であり、研究活動は活発であるが、資金やインフラが限られているため伸び悩んでいます。中国、日本、インドを含むアジア太平洋地域は、医療インフラ整備への多額の投資により、高い疾患罹患率が報告されています。製薬業界の活況がこれらの地域の臨床試験用品市場を牽引しており、その需要はスピードよりも費用対効果に左右されます。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは、臨床試験用品市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、臨床試験用品市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、臨床試験用品市場における現在の立ち位置を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[199 Pages Report] The Clinical Trial Supplies Market size was estimated at USD 3.35 billion in 2023 and expected to reach USD 3.64 billion in 2024, at a CAGR 8.43% to reach USD 5.92 billion by 2030.
Clinical trial supplies are a fundamental yet complex component of clinical research, ultimately helping pave the way toward successful therapeutic breakthroughs and monumental enhancements in patient care pathways. These supplies cater to various research phases, from pre-clinical examinations to post-marketing surveillance studies, thus facilitating the seamless management and execution of clinical investigations. The increasing prevalence of infectious and chronic diseases worldwide and the subsequent rise in clinical trials with research and development expenditure of the pharmaceutical and biopharmaceutical industry stimulates market growth. The high cost associated with clinical trial supplies, stringent regulations for supplies, and cross-border logistics challenges restrict market growth. Growing emphasis on drug development and shifting towards patient-centric clinical trials offer the potential for better clinical trial patient recruitment, study enrollment, and participant retention. In addition, ongoing advancements in a diverse range of clinical trial supplies are expected to open new research avenues for pharmaceutical and biopharmaceutical companies.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.35 billion |
Estimated Year [2024] | USD 3.64 billion |
Forecast Year [2030] | USD 5.92 billion |
CAGR (%) | 8.43% |
Regional Insights
In the Americas, primarily the United States and Canada, there is a significant dependence on clinical trial supplies due to a high diagnosis rate of chronic diseases and robust healthcare infrastructure. Over the past year, the major patents registered revolved around optimizing supply chain models and employing advanced analytics to align trial supply with demand. The European Union (EU), the Middle East, and Africa exhibit a diverse range of needs due to discrepancies in healthcare access and spending. Europe witnesses steady demand for clinical trial supplies, fueled by heavy investments in research and development initiatives and a surge in the geriatric population. In contrast, Middle Eastern and African countries encompass emerging markets with rising research activities yet laid back due to limited funding and infrastructural impediments. Asia-Pacific, including China, Japan, and India, reports a high disease prevalence, bridged by substantial investments in improving healthcare infrastructure. The booming pharmaceutical industry drives the clinical trial supplies market in these regions, and the demand is dictated more by cost-efficacy rather than speed, mirroring their unique healthcare economic dynamics.
Market Insights
The market dynamics represent an ever-changing landscape of the Clinical Trial Supplies Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Clinical Trial Supplies Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Clinical Trial Supplies Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Signal: UK Clinical Research Provider Ergomed Bought Out in USD 888 Million Deal
Permira, a UK private equity firm, agreed to acquire Ergomed for USD 888.1 million. Ergomed is a clinical trial development and management services provider, catering to clients across more than 100 countries. This strategic acquisition can expand Permira's already impressive portfolio of medical companies, including Neurapharm and Cambrex. [Published On: 2023-09-04]
Thermo Fisher Scientific Launches New Smart Refrigerator Series
Thermo Fisher Scientific introduced the Thermo Scientific TM TSG series refrigerators, specifically engineered to cater to the stringent demands of diverse industries. These cutting-edge refrigerators leverage advanced technology to ensure accurate temperature control, effectively preserving the integrity of vaccines and pharmaceuticals. By minimizing temperature fluctuations, these refrigerators effectively mitigate the risks associated with such variations, safeguarding medical products' potency and efficacy. [Published On: 2023-08-16]
Loftware and Tenthpin Collaborate on Clinical Supply Labeling
Loftware and Tenthpin collaborated to launch a software called Loftware Prisym 360, which is specifically designed for clinical supply labeling. The main objective of this partnership is to address the growing challenges faced by clinical trial supply teams within the pharmaceutical industry. This agreement enables both Loftware and Tenthpin to actively promote, educate, and implement a comprehensive content and labeling solution for their clinical customers. [Published On: 2023-08-02]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Clinical Trial Supplies Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Clinical Trial Supplies Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Abbott Laboratories, Almac Group Limited, B. Braun SE, Baxter International, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bruker Corporation, Cardinal Health, Inc., Charles River Laboratories, Inc., COREX LOGISTICS LIMITED, Emsere B.V by Medicapital Holdco B.V., Eppendorf SE, Evident Corporation by Olympus Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Group, Hipro Biotechnology Co., Ltd., Hitachi, Ltd., HORIBA, Ltd., ICON PLC, Immudex ApS, Incyte Corporation, IQVIA Inc., Johnson & Johnson Services, Inc., KLIFO A/S, Labnet International, Leica Microsystems GmbH by Danaher Corporation, llumina, Inc., Lonza Group Ltd., Medline Industries, LP, Merck KGaA, Myonex, LLC, Novo Nordisk A/S, Nuvisan GmbH, Parexel International Corporation, Perceptive Informatics LLC and its affiliates, d/b/a Calyx, PerkinElmer Inc. by Revvity, Inc., Pfizer Inc., Promega Corporation, Recipharm AB, Rubicon Research Pvt. Ltd., Sekisui Diagnostics Group, Sharp Services, LLC, Siemens Healthcare GmbH, Smith & Nephew PLC, Stryker Corporation, Thermo Fisher Scientific Inc., and Woodley Equipment Company Ltd..
Market Segmentation & Coverage